“RNA-based diagnostics have the potential to significantly improve patient stratification, which is at the
heart of precision medicine. It allows us to move beyond the predictive power of DNA, and into true
biomarker expression. Treatment that provides the right drug for the right patient at the right time?
This will help us get there.”
Dr. Natalie LaFranzo
Director of Scientific Projects and Market Development
Cofactor Pinnacle enables the identification of important cancer associated features, not detectable by DNA sequencing alone. Pinnacle is approved for use with >25 cancer types, with clinical validation.
Pinnacle measures the RNA expression of nearly 400 prominent cancer genes, identifies those with oncogenic expression, and enables identification of >180 critical cancer associated gene fusions from any type of formalin-fixed solid tumor.
Are you a translational researcher looking for a more flexible CAP/CLIA product? Contact us to learn more about our RNA-seqDx offering.
|Product Name||Catalog Number||Description||Price per Sample|
|RNA-seqDx||CFGDX-101CFGDx-102||Fresh-Frozen CAP/CLIA RNA sequencing, 30 million single-end readsFresh-Frozen CAP/CLIA RNA sequencing, 60 million single-end reads||$1000$1500|
Learn more about our other offerings.